BiotechTube

Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Diabetic Peripheral Neuropathy

Conditions

Diabetic Peripheral Neuropathy

Trial Timeline

May 14, 2021 → Nov 30, 2022

NCT ID
NCT04846673

About Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg

Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg is a approved stage product being developed by Yuhan for Diabetic Peripheral Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04846673. Target conditions include Diabetic Peripheral Neuropathy.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Peripheral Neuropathy were approved

Approved (20) Terminated (3) Active (0)
✅Anplag(Sarpogrelate) + PlaceboYuhanApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved
✅Mosapride + domperidoneSumitomo PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04846673ApprovedCompleted

Competing Products

20 competing products in Diabetic Peripheral Neuropathy

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CHF6467 activeComac MedicalPhase 1/2
22
Ruboxistaurin mesylateEli LillyPhase 3
40
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
Baricitinib + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Anplag(Sarpogrelate) + PlaceboYuhanApproved
43
CS-3150 + placeboDaiichi SankyoPhase 2
35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
40
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Beraprost sodiumAstellas PharmaPre-clinical
22
ASP8825 + PlaceboAstellas PharmaPhase 2
27